Compared with other non-insulin hypoglycemic drugs, it can not only effectively reduce blood glucose and glycosylated hemoglobin (HbA1c), but also protect cardiovascular system, nervous system and kidney function without causing hypoglycemia and weight gain
This may be related to the high amino acid homology of natural glucagon-like peptide-1, with Liraglutide reaching 97% [56]
21 Remarkably, even in HF-free patients with morbid obesity, cardiac abnormalities can be seen that are consistent with left ventricular (LV) remodelling and dysfunction, including greater LV mass, LV diastolic dysfunction and elevated LV filling pressure
Accordingly, models in animals lacking DPP-4 underline the importance of this factor in the regulation of glucose metabolism: in fact, DPP-4-deficient rats showed better glucose tolerance and higher insulin and GLP-1 levels than controls [51]
Emergence of a new glucoregulatory mechanism for glycemic control with dapagliflozin/exenatide therapy in type 2 diabetes
